CATALYST

Supplementary Appendix 2 – CATALYST WHO dataset

Data category	Information
Primary registry and trial identifying number	EudraCT Number 2020-001684-89
Date of registration in primary registry	15-May-2020
Secondary identifying numbers	ISRCTN: 40580903
Source(s) of monetary or material support	Medical Research Council
Primary sponsor	University of Birmingham
Secondary sponsor(s)	n/a
Contact for public queries	TV: t.v.veenith@bham.ac.uk BF: b.fisher@bham.ac.uk
Contact for scientific queries	TV: t.v.veenith@bham.ac.uk BF: b.fisher@bham.ac.uk
Public title	Which treatment could lessen the severity of a coronavirus infection when compared with usual care in an NHS setting?
Scientific title	A multicentre, open-label, phase II, multi-arm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults
Countries of recruitment	UK
Health condition(s) or problem(s) studied	COVID-19
Intervention(s)	Usual care provided following the current institutional policy for patients with COVID-19
	Usual care combined with namilumab
	Usual care combined with infliximab

UNIVERSITY OF BIRMINGHAM | @CRCTU

CATALYST

Data category	**Information**
Key inclusion and exclusion criteria	Ages eligible for study: ≥16 years Sexes eligible for study: both Accepts healthy volunteers: no
	Inclusion criteria: adult patient (≥ 16 years), patient hospitalised with SARS-CoV-2 pneumonia
	Exclusion criteria: allergy against namilumab or infliximab, pregnancy or breastfeeding women, tuberculosis or other severe (non-SARS-CoV-2) infections
Study type	Interventional
	Allocation: randomised, open-label
	Primary purpose: safety and biological signal for efficacy
	Phase II
Date of first enrolment	May-2020
Target sample size	Up to 60 per arm
Recruitment status	Closed
Primary outcome(s)	C-reactive protein concentration over time (time frame: 28 days)
Key secondary outcome	WHO Clinical Progression Improvement Scale (time frame: 28 days)

UNIVERSITY OF BIRMINGHAM | @CRCTU